Neutrophil fluorescence in septic shock with DIC
Part of Blood & lymphatic, Infections clinical trials.
This study measures a type of white blood cell (neutrophil) fluorescence in patients with septic shock who also have a serious blood clotting condition called disseminated intravascular coagulation (DIC). The goal is to see if this measurement can help doctors better understand or manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the intensive care unit for septic shock (a severe infection that causes low blood pressure).
- You have a condition called disseminated intravascular coagulation (DIC), which affects blood clotting.
- You are not pregnant or breastfeeding.
- You do not have severe liver disease (Child Pugh C cirrhosis).
- You do not have a very low neutrophil count (less than 500 per cubic millimeter of blood).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early signs of dangerous blood clotting complications (called DIC) in patients admitted to intensive care with severe infection. Finding these signs early may help doctors treat the problem faster and improve outcomes.
This study tests whether a special blood test can help doctors quickly identify patients who have serious infections (sepsis) in the emergency department. The test looks at white blood cells that glow under fluorescent light to see if they can predict which patients are at highest risk.
This research study measures special blood markers (microRNAs) in patients with septic shock or critical illness to understand how the body responds to severe infection. Results may help doctors better diagnose and treat sepsis in the future.
This trial studies whether advanced genetic testing (next-generation sequencing) can help doctors better understand and manage neutropenic sepsis—a serious infection risk when white blood cell counts are too low. You may be considered if you develop fever or sepsis quickly (within 24 hours) while your counts are low.
This trial looks at how the immune system changes after septic shock in adults in the ICU. It may help doctors better predict or manage complications by studying blood markers a few days after starting treatment.
This trial tests a new way of giving fluids and medicines to people with septic shock. It focuses on a simple sign called capillary refill time (how fast color returns when you press a fingernail) to guide treatment, aiming to improve recovery.
Hear when a new DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH SEPTIC SHOCK trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.